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Abstract
Basket designs are prospective clinical trials that are devised with the hypothesis that
the presence of selected molecular features determine a patient’s subsequent response to
a particular “targeted” treatment strategy. Basket trials are designed to enroll multiple
clinical subpopulations to which it is assumed that the therapy in question offers bene-
ficial efficacy in the presence of the targeted molecular profile. The treatment, however,
may not offer acceptable efficacy to all subpopulations enrolled. Moreover, for rare dis-
ease settings, such as oncology wherein these trials have become popular, marginal mea-
sures of statistical evidence are difficult to interpret for sparsely enrolled subpopulations.
Consequently, basket trials pose challenges to the traditional paradigm for trial design,
which assumes inter-patient exchangeability. The R-package basket facilitates the analy-
sis of basket trials by implementing multi-source exchangeability models. By evaluating
all possible pairwise exchangeability relationships, this hierarchical modeling framework
facilitates Bayesian posterior shrinkage among a collection of discrete and pre-specified
subpopulations. Analysis functions are provided to implement posterior inference of the
response rates and all possible exchangeability relationships between subpopulations. In
addition, the package can identify “poolable” subsets of and report their response charac-
teristics. The functionality of the package is demonstrated using data from an oncology
study with subpopulations defined by tumor histology.
Keywords: Bayesian analysis, basket design, hierarchical model, master protocol, oncology,
patient heterogeneity.
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2 Basket Trial Analysis with MEM Models
1. Introduction
Basket designs are prospective clinical trials that are devised with the hypothesis that the
presence of selected molecular features determine a patient’s subsequent response to a partic-
ular “targeted” treatment strategy. Central to the design are assumptions 1) that a patient’s
expectation of treatment benefit can be ascertained from accurate characterization of their
molecular profile and 2) that biomarker-guided treatment selection supersedes traditional
clinical indicators for the studied populations, such as primary site of origin or histopathol-
ogy. Thus, basket trials are designed to enroll multiple clinical subpopulations to which it
is assumed that the therapy(s) in question offers beneficial efficacy in the presence of the
targeted molecular profile(s). These designs have become popular as drug developers seek to
conform therapeutic interventions to the individuals being treated with precision medicine
and biomarker-guided therapies. Most basket trials have been conducted within exploratory
settings to evaluate agent-specific estimates of tumor response. Cunanan et al. (Cunanan,
Gonen, Shen, Hyman, Riely, Begg, and Iasonos 2017a) describe three studies implemented
in oncology settings which extend the basic formulation of a basket trial to multiple targets
and/or agent combinations. Most commonly uncontrolled trials, extensions have recently
accommodated a wide variety of potential motivations beyond exploratory studies.
Molecularly targeted treatment strategies may not offer acceptable efficacy to all putatively
promising clinical indications. Early basket trials were criticized for their reliance on bas-
ketwise analysis strategies that suffered from limited power in the presence of imbalanced
enrollment as well as failed to convey to the clinical community evidentiary measures of
heterogeneity among the studied clinical subpopulations, or “baskets”. Acknowledging the
potential for differential effectiveness among the enrolled patient subpopulations by design,
heterogeneity exists as an intrinsic hypothesis in evaluations of treatment efficacy. Moreover,
for rare disease settings, such as oncology wherein these trials have become popular, marginal
measures of statistical evidence are difficult to interpret on the basis of individual basket-wise
analyses for sparsely enrolled subpopulations. Consequently, basket trials pose specific chal-
lenges to the traditional paradigm for trial design, which assume that the patients enrolled
represent a statistically exchangeable cohort.
Hobbs and Landin (2018) extended the Bayesian multisource exchangeability model (MEM)
framework to basket trial design and subpopulations inference. Initially proposed by Kaizer,
Koopmeiners, and Hobbs (2017), the MEM framework addressed the limitations associated
with “single-source” Bayesian hierarchical models, which rely on a single parameter to deter-
mine the extent of influence, or shrinkage, from all sources. In the presence of subpopulations
that arise as mixtures of exchangeable and non-exchangeable subpopulations, single-source
hierarchical models (SEM) are characterized by limited borrowing, even in the absence of
heterogeneity (Kaizer et al. 2017). Moreover, when considering the effectiveness of a particu-
lar treatment strategy targeting a common disease pathway that is observed among differing
histological subtypes, SEMs fail to admit statistical measures that delineate which patient
subtypes should be considered “non-exchangeable” based on the observed data. By way of
contrast, MEM provides a general Bayesian hierarchical modeling strategy accommodating
source-specific smoothing parameters. MEMs yield multi-resolution smoothed estimators that
are asymptotically consistent and accommodate both full and non-exchangeability among
discrete subpopulations. The inclusion of methods for shrinkage of multiple sources is not
restricted to use in basket trial master protocols, but has also been extended in the MEM
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framework to a sequential combinatorial platform trial design where it demonstrated improved
efficiency relative to approaches without information sharing (Kaizer, Hobbs, and Koopmein-
ers 2018).
This paper introduces the basket (Chen, Hobbs, Kaizer, and Kane 2019) package for the
R-programming environment (R Core Team 2019) to analyze basket trials under MEM as-
sumptions. The main analyses conduct full posterior inference with respect to a set of response
rates corresponding to the studied subpopulations. The posterior exchangeability probabil-
ity (PEP) matrix is calculated, which describes the probability that any pair of baskets are
exchangeable. Based on the resultant PEP, subpopulations are clustered into meta-baskets.
Additionally, posterior effective sample sizes are calculated for each basket, describing the ex-
tent of posterior shrinkage achieved. Posterior summaries are reported for both “basketwise”
and “clusterwise” analyses.
The package used in the examples below is available on CRAN at https://cran.r-project.
org/package=basket and it fits into the general category of the “Design and Analysis of
Clinical Trials” (Zhang and Zhang 2018) focusing on uncontrolled, early-phase trial analysis.
The interface is designed to be simple and will readily fit into clinical trial frameworks. It has
been tested using R version 3.5 and the basket package version 1.0.0.
2. Exchangeability for Trials with Subpopulations
2.1. The Single-Source Exchangeability Model
Y1 Y2 Y3 ... YJ
θ1 θ2 θ3 ... θJ
θ
Figure 1: A conventional single-source Bayesian hierarchical model with J subtypes.
Basket trials intrinsically include subpopulations, which require a priori consideration for
inference. When ignored the trial simply pools patients, conducting inference with the implicit
assumption of inter-patient statistical exchangeability, which can induce bias and preclude the
identification of unfavorable/favorable subtypes in the presence of heterogeneity. At the other
extreme, subpopulation-specific analyses assume independence. While attenuating bias, this
approach suffers from low power, especially in rare subpopulations enrolling limited sample
size. Bayesian hierarchical models address this polarity, facilitating information sharing by
“borrowing strength” across subtypes with the intent of boosting the effective sample size of
inference for individual subtypes.
4 Basket Trial Analysis with MEM Models
Single-source exchangeability models (SEM), represent one class of Bayesian hierarchical mod-
els. In the context of a basket trial design, statistical approaches using the SEM framework
rely on a single parametric distributional family to characterize heterogeneity across all sub-
populations, which is computationally tractable but intrinsically reductive in characterization
of heterogeneity. In the presence of both exchangeable and non-exchangeable arms, the SEM
framework tends to favor the extremes of no borrowing or borrowing equally from all sources,
effectively ignoring disjointed singleton subpopulations and meta-subtypes.
Consider a basket trial which enrolls patients from J subpopulations (or subtypes) (j =
1, ..., J), where Yj represents the responses observed among patients in the jth subtypes.
Using i to index each patient, the SEM generally relies on model specifications that assume
that patient-level responses, Yi,j , are exchangeable Bernoulli random variables conditional
on subtype-specific model parameters, e.g. θj . The second-level of the model hierarchy as-
sumes that the collection of subtype-specific model parameters, θ1, ... ,θJ , are statistically
exchangeable through the specification of a common parent distribution. Figure 1 illustrates
this structure, wherein each Yj has its own subtype-specific θj which are further assumed
exchangeable to estimate the overall θ. Examples of SEM approaches are introduced and
discussed by (Berry, Carlin, Lee, and Mu¨ller 2010, chapter 2), Thall, Wathen, Bekele, Cham-
plin, Baker, and Benjamin (2003), and Berry, Broglio, Groshen, and Berry (2013), with Hobbs
and Landin (2018) providing additional background on these specific SEM implementations.
SEM approaches are also implemented in packages by Nia and Davison (2012) and Savage,
Cooke, Darkins, and Xu (2018) and have been extended to more specialized applications
in fMRI studies (Stocco 2014), modeling clearance rates of parasites in biological organisms
(Sharifi-Malvajerdi, Zhu, Fogarty, Fay, Fairhurst, Flegg, Stepniewska, and Small 2019), mod-
eling genomic bifurcations (Campbell and Yau 2017), modeling ChIP-seq data through hidden
Ising models (Mo 2018), modeling genome-wide nucleosome positioning with high-throughput
short-read data (Samb, Khadraoui, Belleau, Descheˆnes, Lakhal-Chaieb, and Droit 2015), and
modeling cross-study analysis of differential gene expression (Scharpf, Tjelmeland, Parmigiani,
and Nobel 2009).
While integrating inter-cohort information, SEMs are limited by assumptions of exchange-
ability among all cohorts. That is, the joint distribution P(Y1, Y2, ..., Yk) is invariant under a
permutation describing subpopulation subsets. P(Y1, Y2, ..., Yk) = (Yk, ..., Y2, Y1). SEMs are
“single-source” in the sense that the model uses a single set of parameters to characterize het-
erogeneity such that the statistical exchangeability of model parameters is always assumed.
Violations of these assumptions with analyses of response rates in clinical trials yields bias,
potentially inflating the estimated evidence of an effective response rate for poorly responding
cohort or minimizing the effect in effective subsets. These assumptions have resulted in poor
results for frequentist power when controlling for strong type I error, leading some cancer
trialists to question the utility of Bayesian hierarchical models for phase II trials enrolling
discrete subtypes (Freidlin and Korn 2013; Cunanan, Iasonos, Shen, Hyman, Riely, Go¨nen,
and Begg 2017b).
2.2. The Multi-source Exchangeability Model
Limitations of SEM can be overcome through model specification devised to explicitly char-
acterize the evidence for exchangeability among collections of subpopulations enrolling in a
clinical trial. Multi-source exchangeability models (MEM) produce cohort-specific smoothing
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parameters that can be estimated in the presence of the data to facilitate dynamic multi-
resolution smoothed estimators that reflect the extent to which subsets of subpopulations
should be consider exchangeable. Shown to be asymptotically consistent, MEMs were ini-
tially proposed by Kaizer et al. (2017) for “asymmetric” cases wherein a primary data source
is designated for inference in the presence of potentially non-exchangeable supplemental data
sources. The framework was extended by Hobbs and Landin (2018) to the “symmetric” case
wherein no single source or subtype is designated as primary (e.g., a basket trial). The sym-
metric MEM approach considers all possible pairwise exchangeability relationships among J
subpopulations and estimates the probability that any subset of subpopulations should be
considered statistically exchangeable (or poolable).
The symmetric MEM is the motivation and focus of the basket package. While SEMs are
parameterized by a single set of parameters θ, the MEM may have up to J (the number of
subtypes) sources of exchangeability with each set of data Yj contributing to only one set of
parameters. All possible combinations of exchangeability can be enumerated, denoted as K
possible configurations (Ωk, k = 1, ...,K).
Y1 Y2 Y3
θ1 θ2
(a) Model where Y1 and Y2 are exchangeable.
Y1 Y2 Y3
θ1 θ2
(b) Model where Y1 and Y3 are exchangeable.
Figure 2: Two example exchangeability configurations of the MEM.
Model Description
Figure 2 depicts two possible MEMs among three subpopulations wherein at least two subpop-
ulations are statistically exchangeable. Both examples comprise two “sources” of exchange-
ability for inference, with Y1 and Y2 combined to represent one “source” to estimate θ1 and Y3
to estimate θ2 in (a) and Y1 and Y3 combined in (b). Implementation of basket considers the
number of “sources” ranging from one (as in the single-source case), wherein all subtypes are
pooled together, to J , the total number of subtypes. The MEM Bayesian model specification
facilitates posterior inference with respect to all possible pairwise exchangeability relationships
among J subpopulations. The framework facilitates estimation of disjointed subpopulations
comprised of meta-subtypes or singelton subtypes and thereby offers additional flexibility
when compared to SEM specifications.
The set space of all possible pairwise exchangeability relationships among a collection of J
discrete cohorts can be represented by a symmetric J ×J matrix Ω with element Ωij = Ωji ∈
[0, 1] with value 1 (0) indicating that patients of subtype i are statistically exchangeable with
(independent of) patients of subtype j. Without additional patient-level characteristics, it is
assumed patients within an identical subtype are assumed to be statistically exchangeable.
That is Ωii = 1 for {i : 1, ..., J}. There are K =
∏J−1
j=1 2
j possible configurations of Ω, each
representing one possible pairwise exchangeability relationship among the J subtypes. The
framework differs fundamentally from SEM in that it allows for the existence of multiple closed
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subpopulations (or cliques) comprised of fully exchangeable subtypes. Therefore, following
the terminology of Kaizer et al. (2017) we refer to each possible configuration of Ω as a MEM.
For a basket trial designed to enroll a total of N patients in J baskets, let yij = 1 indicate
the occurrence of a successful response for the ith patient enrolled in basket j, and 0 indicate
treatment failure. Let nj denote the number of patients observed in basket j and denote the
total number of responses in basket j by Sj =
∑nj
i=1 yij . The set {S1, S2, ..., SJ} is denoted S.
Let pi = {pi1, pi2, ...piJ} vectorize the set of response rates such that pij denotes the probability
of response for jth basket and Sj ∼Bin(nj , pij) with prior distribution pij ∼ Beta(aj , bj).
Let B() denote the beta function. Given an exchangeability configuration Ωj , the marginal
density of Sj follows as (see Hobbs and Landin 2018, for details)
m(Sj |Ωj , S(−j)) ∝
B
(
a+
∑J
h=1 Ωj,hSh, b+
∑J
k=1 Ωj,k(nk − Sk
)
B(a, b)
×
J∏
i=1
(
B(a+ Si, b+ ni − Si)
B(a, b)
)1−Ωj,i
.
(1)
Marginal posterior inference with respect to pij | S averages the conditional posterior of pij |
Ωj , S with respect to the marginal posterior probability of G = 2
J−1 possible exchangeability
configurations of Ωj . Let ω = {ω1, ..., ωG} denote the collection of vectors each of length
J that collectively span the sample space of Ωj . The marginal posterior distribution can be
represented by a finite mixture density
q(pij |S) ∝
G∑
g=1
q(pij | S,Ωj = ωg)Pr(Ωj = ωg | S), (2)
where the posterior probability of exchangeability configuration ωg given the observed data
follows from Bayes’ Theorem in proportion to the marginal density of the data given ωg and
its unconditional prior probability
Pr(Ωj = ωg | S) ∝
m(Sj |Ωj = ωg, S(−j))Pr(Ωj = ωg)∑G
u=1m(Sj |Ωj = ωu, S(−j))Pr(Ωj = ωu)
. (3)
Model specification for the symmetric MEM method is described in detail by Hobbs and
Landin (2018).
Estimating Basketwise Exchangeability
The basket package computes the posterior probability that subpopulations i and j should be
considered statistically exchangeable. The collection of all pairwise posterior exchangeability
probabilities (PEP) is denoted in the output as the PEP matrix. Additionally, basket identifies
the maximum a posteriori (MAP) multisource exchangeability model.
Let O denote the entire sample domain of Ω comprised of K = ∏J−1j=1 2j strictly symmetric
MEMs. The PEP matrix is obtained by evaluating the union of MEMs for which Ωij = 1
over the sample domain of O,
P(Ωij = 1|S) =
∑
Ω∈O
1{Ωij=1} P(Ω|S),
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where P(Ω|S) is the product of row-wise calculations specified in Equation 3. Note that there
are K/2 MEM configurations in the space of O where Ωij = 1. The MAP follows as the MEM
configuration that attains maximum Pr(Ω | S) over O.
Effective Sample Size
Measurement of the extent to which information has been shared across sources in the context
of a Bayesian analysis is best characterized by the effective sample size (ESS) of the resultant
posterior distribution Hobbs, Carlin, and Sargent (2013); Murray, Hobbs, and Carlin (2015).
ESS quantifies the extent of information sharing, or Bayesian “shrinkage,” as the number of
samples that would be required to obtain the extent of posterior precision achieved by the
candidate posterior distribution when analyzed using a vague“reference”or maximum entropy
prior. Calculation of the ESS in basket deviates from the approach suggested in Hobbs and
Landin (2018), which is sensitive to heavy-tailed posteriors. Robustness is introduced with
basket through beta distributional approximation, which yields more conservative estimates
of ESS. Specifically, the simulated annealing algorithm (implemented with GenSA package
Yang Xiang, Gubian, Suomela, and Hoeng (2013)) is used to identify the parametric beta
distribution with minimal Euclidean distance between the interval boundaries obtained from
the posterior estimated HPD interval and the corresponding beta 1−hpd_alpha Bayesian
credible interval. Shape parameters attained from the “nearest” parametric beta distribution
are summed to yield estimates of posterior ESS for each basket and cluster.
Posterior Probability
Basket trials are devised for the purpose of testing the hypothesis that a targeted treatment
strategy achieves sufficiently promising activity among a partition of the targeted patient
population. The MEM framework acknowledges the potential for heterogeneity with respect
to the effectiveness of the enrolled patient subpopulations or baskets. Within the MEM
framework, this testing procedure follows from the cumulative density function (cdf) of the
marginal posterior distribution (2). Specifically, the posterior probability that pij exceeds a
null value pi0 is computed by the weighted average of cdfs for all possible exchangeability
configurations. Basket implements this computation and allows for subpopulation-specific
values of the null hypothesis, pi0, which quantify differing benchmarks for effectiveness among
the studied baskets. Note that this feature accommodates basket formulation on the basis of
varying levels of clinical prognosis.
3. Package Overview
The basket package facilitates implementation of the binary, symmetric multi-source ex-
changeability model with posterior inference arising with both exact computation and Markov
chain Monte Carlo sampling. The user is required to input vectors that describe the number
of samples (size) and observed successes (responses) corresponding to each subpopulation
(or basket). Analysis output includes full posterior samples, highest posterior density (HPD)
interval boundaries, effective sample sizes (ESS), mean and median posterior estimates, pos-
terior exchangeability probability matrices, and the maximum a posteriori MEM. In addition
to providing “basketwise” analyses, the package includes similar calculations for “clusterwise”
analyses for which subgroups are combined into meta-baskets, or clusters, using a graphical
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clustering algorithm implemented with the igraph package that treats the posterior exchange-
ability probabilities as edge weights. A specific clustering algorithm is specified via argument
cluster_function which is set to "cluster_louvain" by default. In addition, plotting tools
are provided to visualize basket and cluster densities as well as their exchangeability.
Analysis requires the specification of beta shape parameters (shape1 and shape2) for the prior
distributions of the basketwise response probabilities pij . Shape parameter arguments may be
specified as single positive real values, by which identical prior distributions are assumed for
all pij , or as vectors of length J with each pair of shape1 and shape2 values corresponding
to each basket. Arguments shape1 and shape2 assume values 0.5 by default characterizing
prior distributions with the effective sample size of 1 patient for each pij .
The user must additionally specify the symmetric matrix of prior exchangeability probabilities
(prior). The model assumes that exchangeable information is contributed among patients
enrolling into a common basket. Thus, all diagonal entries of prior must assume value 1.
Off-diagonal entries, however, quantify the a priori belief that each pair of subpopulations
represents an exchangeable unit. Thus, off-diagonal cells of prior may assume any values on
the unit interval. Basket assumes the “reference” prior proposed by Hobbs and Landin (2018)
as the default setting for which all off-diagonal cells assume prior probability 0.5, and thus
are unbiased with respect to exchangeability in the absence of the data.
Evidence for sufficient activity is reported by basket and cluster as posterior probabilities.
Posterior probability calculations require the further specification of either a null response
rate or vector of null response rates corresponding to each basket (p0 set to 0.15 by default)
as well as the direction of evaluation (alternative set to “greater” by default). Additionally,
summary functions report the posterior estimates by basket and cluster. The highest posterior
density (HPD) is calculated for a given a level of probabilistic significance (hpd_alpha set to
0.05 by default).
Bayesian computation is implemented by two methods: the exact method (mem_exact() func-
tion) and the Markov chain Monte Carlo (MCMC) sampling method (mem_mcmc() function).
mem_mcmc() is the preferred method. mem_exact() provides slightly more precise estimates
than the former but scales poorly in number of baskets. The discrepancy in precision between
exact and sampling-based implementations is easily controlled by specifying a larger number
of MCMC iterations (num_iter set to 2e+05 by default) in mem_mcmc().
3.1. The Exact Method and the MCMC Method
Implementation of mem_exact() conducts posterior inference through enumeration of the
entire sample domain of MEMs, denoted O above. Facilitating precise calculation of the
posterior estimators, mem_exact() is computationally feasible only in the presence of a small
number of subpopulations. Increasing the size of J increases the number of configurations in
O by order of O(2J2). Thus, the exact computation is impractical for large values of J . We
recommend its use for J < 7.
Our MCMC sampling method, formulated from the Metropolis algorithm (see e.g. Gelman,
Carlin, Stern, and Rubin 2013), extends the model’s implementation to larger collections
of subpopulations, which currently accommodates more than J = 20 baskets. Specifically,
MCMC sampling is used to approximate the posterior distribution P(Ωj = ωg|S). Imple-
mentation of mem_mcmc() requires the specification of an initial MEM matrix (initial_mem)
used as the starting point for Ω from which to initiate the Metropolis algorithm. Argument
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Method Return Description
basket_pep Basketwise PEP matrix
basket_map Basketwise maximum a posteriori probability (MAP) matrix
cluster_baskets Basket assignments for each cluster
cluster_pep Clusterwise PEP matrix
cluster_map Clusterwise MAP matrix
Table 1: MEM model accessor functions.
initial_mem is set to round(prior - 0.001) by default, which for the default setting of
prior yields the identity matrix.
The MCMC algorithm proceeds in iterative fashion with each step selecting a random number
of cells of Ω to flip from 0 to 1 or from 1 to 0 to produce a new candidate MEM which
we denote Ω∗. Acceptance criteria for the candidate Ω∗ compares the marginal posterior
density of Ω∗ and its unconditional prior distribution with respect to the last accepted MEM
matrix configuration. Denote the sum of log marginal posterior density and prior distribution
with new candidate MEM configuration by D∗ and previously accepted configuration by D0,
respectively. If D∗ − D0 ≥ 0, the candidate configuration is accepted. Otherwise, the new
configuration is accepted randomly with probability exp (D∗ −D0). For each sampled Ω
configuration, pij , is sample from its conditional posterior distribution for all j = 1, ..., J.
The algorithm initiates with a burn-in period (mcmc_burnin set to 50,000 by default). Dis-
carding the burn-in samples, PEP calculation with mem_mcmc() evaluates the distribution of
sampled MEMs, reporting for all basket pair combinations the proportion of samples that
identify basket i as exchangeable with basket j. The MAP calculation reports the posterior
mode or most frequently sampled MEM. Bayesian computation facilitated by mem_mcmc()
scales MEM analyses to more than 20 baskets. Specification of the size of the MCMC itera-
tions (num_iter) is pivotal to attaining precise estimates of the resultant posterior quantities.
Our investigations support the default value of 2e+05 as a practical lower bound. In prac-
tice, one may gradually increase the number of the MCMC iterations until the resultant PEP
matrix converges to stable values.
3.2. MEM Data Structure and Associated Methods
Analysis functions mem_mcmc() and mem_exact() are parameterized almost identically, with
the former requiring extra arguments that control the MCMC algorithm: the current seed
(for reproducibility), the length of burn-in and number of MCMC iterations for computa-
tion of posterior quantities, and an initial MEM matrix from which to start the algorithm.
Function arguments are specified with reasonable default values for implementation of either
analysis type. Both functions return a common list data structure. Both are derived from an
abstract S3 "exchangeability_model" class with concrete type "mem_mcmc" or "mem_exact"
depending on which function generated the analysis. The two data structures differ only by
extra elements included with "mem_mcmc" objects to control implementation of the MCMC
algorithm. For convenience, and to promote using "mem_mcmc" by default, a wrapper function
basket() was created. The method argument allows the user to specify the analysis function
as either MCMC (via "mcmc") or exact (via "exact"). By default the argument is set to
"mcmc".
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MEM or “exchangeability” objects are composed of named elements. The first, "call" is
the expression used to generate the analysis. Second is the "basket" element, which is a list
with concrete class mem_basket, derived from the mem abstract class. Basket reports posterior
estimates of trial subpopulations including the PEP, HPD interval, posterior probability, ESS,
and other distribution characteristics. The "cluster" element comprises a list with concrete
class mem_cluster and abstract class mem which contains posterior estimates for clusters rather
than baskets. In addition to these three elements, an mem_mcmc object will also contain the
seed used to generate the results. This value can be used to reproduce subsequent analyses.
Because they are relatively complex, a summary function is implemented to summarize the
components relevant to exchangeability models for trial analysis. The
summary.exchangeability_model() method returns an object of type "mem_summary". A
print.mem_summary() method is provided for a user-readable summary of the trial. Be-
cause there is little distinction between an exchangeability_model object and its summary,
print.exchageability_model() method prints the summary object.
The mem_summary object provides access to the overall study characteristic. Accessor methods
are also provided to extract other key information from the analysis objects at both the basket
and cluster levels. These functions and their descriptions are given in Table 1. In addition, a
complete MEM analysis is computationally intensive; altering the null response rate need not
imply rerunning the entire analysis. To facilitate partial analysis updates under a new null
(argument p0), the update_p0() function is provided. Likewise samples can be drawn from
the posterior distribution of the basket and cluster models using the sample_posterior()
function.
3.3. Basketwise and Clusterwise Visualization
Two types of functions are provided for visualizing the results of an MEM analysis, both of
which are supported at basket and cluster levels of inference. Density plotting is available with
the plot_density() functions, which produce graphs depicting the posterior distributions of
response probabilities at the basket and cluster level. Additionally, functions for visualizing
exchangeability relationships are provided in a manner similar to correlograms. Since the
values visualized are exchangeability, rather than correlation, we have termed these plots
exchangeograms. These can be plotted for PEP and MAP matrices using the plot_pep()
and plot_map() functions, respectively.
4. Case Study: The Vemurafenib Basket Trial
The “Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations” study (Hy-
man, Puzanov, Subbiah, Faris, Chau, Blay, Wolf, Raje, Diamond, Hollebecque et al. 2015),
enrolled patients into predetermined baskets that were determined by organ site with pri-
mary end point defined by Response Evaluation Criteria in Solid Tumors (RECIST), version
1.1 (Eisenhauer, Therasse, Bogaerts, Schwartz, Sargent, Ford, Dancey, Arbuck, Gwyther,
Mooney et al. 2009) or the criteria of the International Myeloma Working Group (IMWG)
(Durie, Harousseau, Miguel, Blade, Barlogie, Anderson, Gertz, Dimopoulos, Westin, Sonn-
eveld et al. 2006). Statistical evidence for preliminary clinical efficacy was obtained through
estimation of the organ-specific objective response rates at 8 weeks following the initiation
of treatment. This section demonstrates the implementation of basket through analysis of
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Basket Enrolled Evaluable Responses Response Rate
NSCLC 20 19 8 0.421
CRC (vemu) 10 10 0 0.000
CRC (vemu+cetu) 27 26 1 0.038
Bile Duct 8 8 1 0.125
ECD or LCH 18 14 6 0.429
ATC 7 7 2 0.286
Table 2: Vemurafenib trial enrollment and responses.
six organs comprising non–small-cell lung cancer (NSCLC), cholangiocarcinoma (Bile Duct),
Erdheim–Chester disease or Langerhans’-cell histiocytosis (ECD/LCH), anaplastic thyroid
cancer (ATC), and colorectal cancer (CRC) which formed two cohorts. Patients with CRC
were initially administered vemurafenib. The study was later amended to evaluate vemu-
rafenib in combination with cetuximab for CRC which comprised a new basket. Observed
outcomes are summarized in Table 2 by basket. Included in the basket package, the dataset
is accessible in short vemu_wide as well as long formats vemu.
Inspection of Table 2 reveals heterogeneity among the studied baskets. CRC (vemu), CRC
(vemu+cetu), and Bile Duct had relatively low response rates when compared to other bas-
kets, suggesting that patients presenting the BRAF V600 mutation may not yield exchange-
able information for statistical characterization of the effectiveness of the targeted therapy.
Therefore, the MEM framework is implemented to measure the extent of basketwise hetero-
geneity and evaluate the effectiveness of the targeted therapy on the basis of its resultant
multi-resolution smoothed posterior distributions. Hobbs, Kane, Hong, and Landin (2018)
present a permutation study which extends the evaluation of heterogeneity to evaluate sum-
maries of patient attributes reported in Table 1 of the aforementioned trial report. This case
study reports posterior probabilities evaluating the evidence that the response probability for
each organ-site exceeds the null rate of p0 = 0.25.
The analysis can be reproduced by loading the vemu_wide data, which is included with the
package. The data set includes the number of evaluable patients (column evaluable), the
number of responding patients (column responders), and the associated baskets for the
respective results (column baskets). The model is fit by passing these values to the basket()
function along with an argument specifying the null response rate of 0.25 for evaluation of
each basket. The results are shown by passing the fitted model object to the summary()
function. Code to perform the analysis as well as produce the output is shown below.
data(vemu_wide)
vm <- basket(vemu_wide$responders, vemu_wide$evaluable,
vemu_wide$baskets, p0 = 0.25)
summary(vm)
-- The MEM Model Call ----------------------------------------------------------
mem_mcmc(responses = vemu_wide$responders, size = vemu_wide$evaluable,
name = vemu_wide$baskets, p0 = 0.25, mcmc_iter = 2e+05)
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-- The Basket Summary ----------------------------------------------------------
The Null Response Rates (alternative is greater):
NSCLC CRC (vemu) CRC (vemu+cetu) Bile Duct ECD or LCH ATC
Null 0.250 0.250 0.25 0.250 0.250 0.250
Posterior Prob 0.971 0.002 0.00 0.229 0.968 0.896
Posterior Mean and Median Response Rates:
NSCLC CRC (vemu) CRC (vemu+cetu) Bile Duct ECD or LCH ATC
Mean 0.395 0.054 0.052 0.148 0.394 0.360
Median 0.392 0.046 0.045 0.096 0.391 0.363
Highest Posterior Density Interval with Coverage Probability 0.95:
NSCLC CRC (vemu) CRC (vemu+cetu) Bile Duct ECD or LCH ATC
Lower Bound 0.243 0.000 0.001 0.004 0.240 0.178
Upper Bound 0.553 0.129 0.121 0.402 0.553 0.555
Posterior Effective Sample Size:
NSCLC CRC (vemu) CRC (vemu+cetu) Bile Duct ECD or LCH ATC
36.739 49.585 55.031 10.553 36.014 23.542
-- The Cluster Summary ---------------------------------------------------------
Cluster 1
"CRC (vemu)" "CRC (vemu+cetu)" "Bile Duct"
Cluster 2
"NSCLC" "ECD or LCH" "ATC"
The Null Response Rates (alternative is greater):
Cluster 1 Cluster 2
Null 0.250 0.250
Posterior Prob 0.077 0.945
Posterior Mean and Median Response Rates:
Cluster 1 Cluster 2
Mean 0.085 0.383
Median 0.056 0.383
Highest Posterior Density Interval with Coverage Probability 0.95:
Cluster 1 Cluster 2
Lower Bound 0.000 0.221
Upper Bound 0.316 0.556
Posterior Effective Sample Size:
Cluster 1 Cluster 2
9.528 30.779
Journal of Statistical Software 13
Bayesian MEM analysis using the MCMC sampler with reference prior distribution for ex-
changeability identifies the most likely MEM to be comprised of two closed subgraphs (or
meta-baskets). Cluster 1 consists of CRC.v with CRC.vc and BD, while cluster 2 is comprised
of NSCLC, ED.LH, and ATC. Cluster 1 results in an estimated posterior mean response rate
of 0.087. The posterior probability that baskets assigned to cluster 1 exceed the null response
rate of 0.25 is only 0.082. Conversely, attaining a posterior probability of 0.944 and posterior
mean of 0.382, indications identified in cluster 2 demonstrate more promising indications of
activity. Figures 3a and 3b depict full posterior distributions of response probabilities for
each basket and cluster produced by the plot_density() function.
plot_density(vm, type = "basket")
plot_density(vm, type = "cluster")
(a) Posterior basket response density. (b) Posterior cluster response density.
Figure 3: Posterior distributions of the MEM analysis.
The resultant posterior probability of each pairwise exchangeability relationship (PEP) is
summarized with the basket_pep() function and depicted in Figure 4 by application of the
plot_pep() function. The results demonstrate that the posterior exchangeability between the
high-response baskets is higher than that of the lower responding baskets. For example, the
posterior probability that vemurafenib offers identical effectiveness for NSCLC and ED.LH
patients is 0.938. Similarly, the analysis resulted in PEPs of 0.86 for the pairwise relation-
ships between NSCLC with ATC and ED.LH with ATC. The study provided strong support to
conclude that vemurafenib is identically ineffective among CRC.v and CRC.vc subtypes with
PEP = 0.92. The effectiveness of BD was identified as marginally exchangeable with CRC.v
and CRC.vc with PEP = 0.64 and 0.63, respectively. Conversely, both NSCLC and ED.LH
resulted in PEPs of 0 for each CRC basket, demonstrating strong evidence of differential ac-
tivity among these indications. Thus, definitive trials devised to estimate population-averaged
effects should not expect these subtypes to comprise statistically exchangeable patients.
basket_pep(vm)
plot_pep(vm$basket)
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NSCLC CRC (vemu) CRC (vemu+cetu) Bile Duct ECD or LCH ATC
NSCLC 1.000 0.002 0.000 0.231 0.938 0.866
CRC (vemu) 0.002 1.000 0.917 0.643 0.002 0.068
CRC (vemu+cetu) 0.000 0.917 1.000 0.626 0.000 0.031
Bile Duct 0.231 0.643 0.626 1.000 0.243 0.536
ECD or LCH 0.938 0.002 0.000 0.243 1.000 0.861
ATC 0.866 0.068 0.031 0.536 0.861 1.000
Figure 4: The exchangeogram for the Vemurafenib study.
5. Summary
With the emergence of molecularly targeted therapies, contemporary trials are devised to
enroll potentially heterogeneous patient populations defined by a common treatment tar-
get. Consequently, characterization of subpopulation heterogeneity has become central to the
design and analysis of clinical trials, in oncology in particular. By partitioning the study pop-
ulation into subpopulations that comprise potentially non-exchangeable patient cohorts, the
basket design framework can be used to study treatment heterogeneity in a prospective man-
ner. When applied in this context, the Bayesian multisource exchangeability model (MEM)
methodology refines the estimation of treatment effectiveness to specific subpopulations. Ad-
ditionally, the MEM inferential strategy objectively identifies which patient subpopulations
should be considered exchangeable and to what extent.
This article introduced the R package basket as well as demonstrated its implementation
for basket trial analysis using the MEM methodology. An oncology case study using data
acquired from a basket trial was presented and used to demonstrate the main functionality
of the package. Basket is the first available software package implementing Bayesian analysis
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with the MEM. The package is being actively maintained and used in ongoing trials.
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